SCHEMBL4031715

SCHEMBL4031715

CCC(=O)C(C)(C)SCC(=O)O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 1/20 0.39
CYP2D6 P10635 4/20 0.36
CYP2C19 P33261 2/20 0.36
HIF1A Q16665 2/20 0.36
GMNN O75496 1/20 0.33
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
CYP2C9 P11712 1/20 0.33
BLM P54132 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ALDH1A1 P00352 1/20 0.32
HMGCR P04035 1/20 0.32
CHRM1 P11229 1/20 0.32
TBXA2R P21731 1/20 0.32
ADRA1A P35348 1/20 0.32
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4034681 0.75 GAA (0.41) CYP2C19TP53POLBCYP2C9HSD17B10
SCHEMBL25659032 0.74 CYP2D6 (0.38) CYP2D6CYP2C19HIF1AGMNNTP53
SCHEMBL2223767 0.72
SCHEMBL8725908 0.72 CYP2D6 (0.45) FFAR3CYP2D6CYP2C19HIF1AGMNN
SCHEMBL6701234 0.72 CYP2D6 (0.45) FFAR3CYP2D6CYP2C19HIF1AGMNN
SCHEMBL14549079 0.70
SCHEMBL26036469 0.70 DGAT1 (0.39) CYP2D6CYP2C19HIF1AALDH1A1HMGCR
SCHEMBL9174852 0.69 CYP2D6 (0.41) FFAR3CYP2D6CYP2C19HIF1AGMNN
SCHEMBL13130591 0.68 HSD17B10 (0.38) FFAR3CYP2D6CYP2C19HIF1AGMNN
SCHEMBL13129910 0.68 CYP2D6 (0.42) FFAR3CYP2D6CYP2C19HIF1AGMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1687301-B1 THIAEPOTHILONE FOR TREATING CANCEROUS DISEASES LEIBNIZ INST FUER PFLANZENBIOC (DE) 2009-05-13 EP claimed
EP-1687301-B1 THIAEPOTHILONE FOR TREATING CANCEROUS DISEASES LEIBNIZ INST FUER PFLANZENBIOC (DE) 2009-05-13 EP disclosed
EP-1687301-B1 THIAEPOTHILONE FOR TREATING CANCEROUS DISEASES LEIBNIZ INST FUER PFLANZENBIOC (DE) 2009-05-13 EP disclosed
US-7381743-B2 Macrocycles for the treatment of cancer LEIBNIZ-INSTITUT FUER PFLANZENBIOCHEMIE (IPB) (DE) 2008-06-03 US disclosed
US-7381743-B2 Macrocycles for the treatment of cancer LEIBNIZ-INSTITUT FUER PFLANZENBIOCHEMIE (IPB) (DE) 2008-06-03 US disclosed
US-7381743-B2 Macrocycles for the treatment of cancer LEIBNIZ-INSTITUT FUER PFLANZENBIOCHEMIE (IPB) (DE) 2008-06-03 US disclosed
US-20070105905-A1 Novel macrocycles for the treatment of cancer LEIBNIZ-INSTITUT FUER PFLANZENBIOCHEMIE (IPB) (DE) 2007-05-10 US disclosed
US-20070105905-A1 Novel macrocycles for the treatment of cancer LEIBNIZ-INSTITUT FUER PFLANZENBIOCHEMIE (IPB) (DE) 2007-05-10 US disclosed
US-20070105905-A1 Novel macrocycles for the treatment of cancer LEIBNIZ-INSTITUT FUER PFLANZENBIOCHEMIE (IPB) (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105905-A1 Novel macrocycles for the treatment of cancer HCCS, FOLR1, AURKAIP1 FFAR3 3736/4885CYP2D6 963/4885CYP2C19 1061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.